ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SU-OR48

Albuminuria in Kidney Transplantation Patients Predicts Cardiovascular Morbidity After Two Years

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Bielopolski, Dana, The Rockefeller University, New York, United States
  • Rahamimov, Ruth, Rabin Medical Center, Petah Tikva, Israel
  • Zingerman, Boris, Rabin Medical Center, Petah Tikva, Israel
  • Chagnac, Avry, Rabin Medical Center, Petah Tikva, Israel
  • Azulay gitter, Limor, Rabin Medical Center, Petah Tikva, Israel
  • Rozen-zvi, Benaya, Rabin Medical Center, Petah Tikva, Israel

Moderately Increased Albuminuria (MIA) is a well characterized marker of kidney malfunction, both in diabetic and non-diabetic populations, and is used as a prognostic marker for cardiovascular morbidity and mortality. A few studies implied that it has the same value in kidney transplanted patients, but the information relies on spot or dipstick urine protein evaluations, rather than the gold standard of timed urine collection.


We revisited a cohort of 286 kidney transplanted patients, several years after completing a meticulously timed urine collection and assessed the prevalence of major cardiovascular adverse events (MACE) in relation to albuminuria.


During a median follow up of 8.3 years (IQR 6.4-9.1) 144 outcome events occurred in 101 patients. By Kaplan-Meier analysis MIA was associated with increased rate of CV outcome or death (p=0.03), and this was still significant after stratification according to propensity score quartiles (p=0.048). Time dependent Cox proportional hazard analysis showed independent association between MIA and CV outcomes two years following MIA detection (HR 1.83, 95% CI 1.07-2.96).


Two years after documenting MIA in kidney transplanted patients, their CVD risk was increased, most likely, as a result of endothelial dysfunction. This should prompt the caregiver for strict primary prevention and risk factors modification.

Kaplan-Meier analysis showing rate of CV outcome or death in relation to MIA. X axis shows days since urine collection, Y axis shows cumulative survival. Blue curve – patients without MIA, red curve – patients with MIA.